Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Incyte Corp INCY

Healthcare Biotechnology
Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company operates in two therapeutic areas, One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is... see more

Recent & Breaking News (NDAQ:INCY)

Incyte Reports 2017 Third-Quarter Financial Results and Updates on Key Clinical Programs

Business Wire October 31, 2017

Incyte and AstraZeneca to Enter Clinical Trial Collaboration in Early Lung Cancer

Business Wire October 31, 2017

Incyte Names New Member to Its Board of Directors

Business Wire October 30, 2017

Incyte and MacroGenics Announce Global Collaboration and Licensing Agreement for Anti-PD-1 Monoclonal Antibody MGA012

Business Wire October 25, 2017

Incyte to Present at Upcoming Investor Conference

Business Wire October 24, 2017

Incyte to Report Third Quarter Financial Results

Business Wire October 12, 2017

Incyte and Cancer Support Community Delaware Announce the Establishment of the Incyte Cancer Care Assistance Fund for Delaware

Business Wire October 6, 2017

Stocks Under Scanner in the Biotech Space -- ImmunoGen, Incyte, Infinity Pharma, and Insmed

PR Newswire October 5, 2017

Merus Announces Second Quarter 2017 Financial Results and Highlights Recent Progress

GlobeNewswire September 19, 2017

Incyte Corporation (Nasdaq: INCY) to Ring The Nasdaq Stock Market Closing Bell

GlobeNewswire September 18, 2017

Baricitinib Meets Primary Endpoint in Phase 2 Study of Patients with Moderate-to-Severe Atopic Dermatitis

PR Newswire September 14, 2017

Les données de survie sans progression de l'essai ECHO-202 sur l'épacadostat d'Incyte en combinaison avec le KEYTRUDA® (pembrolizumab) mettent en avant la durabilité de la réponse chez les patients atteints de mélanome avancé

Business Wire September 9, 2017

Progression-Free Survival Data from ECHO-202 Trial of Incyte’s Epacadostat in Combination with Merck’s KEYTRUDA® (pembrolizumab) Underscore Durability of Response in Patients with Advanced Melanoma

Business Wire September 9, 2017

Incyte Announces Pricing of Public Offering of 4,945,000 Shares of Common Stock

Business Wire September 8, 2017

Incyte Announces Proposed Public Offering of 4,945,000 Shares of Common Stock

Business Wire September 7, 2017

Incyte Supports the Myeloproliferative Neoplasm (MPN) Community During Blood Cancer Awareness Month

Business Wire September 1, 2017

De nouvelles données pour l'épacadostat en combinaison avec le KEYTRUDA® (pembrolizumab) font état de réponses durables chez les patients atteints de mélanome avancé

Business Wire August 31, 2017

New Data for Epacadostat in Combination with KEYTRUDA® (pembrolizumab) Demonstrate Durable Responses in Patients with Advanced Melanoma

Business Wire August 30, 2017

Lilly to File Baricitinib Resubmission to U.S. FDA before end of January 2018

PR Newswire August 30, 2017

Technical Snapshots for These Biotech Stocks -- ImmunoGen, Incyte, Infinity Pharma, and Jazz Pharma

PR Newswire August 11, 2017